- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00567996
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control
A 26-week Treatment, Multi-center, Randomized, Double-blind, Double- Dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, and Safety of Indacaterol (150 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Salmeterol (50 µg b.i.d.) as an Active Control
연구 개요
상태
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Changhua, 대만
- Novartis Investigator Site
-
Kaohsiung, 대만
- Novartis Investigator Site
-
Kaohusing, 대만
- Novartis Investigator Site
-
Lin-ko, 대만
- Novartis Investigator Site
-
Taichung, 대만
- Novartis Investigator Site
-
Taipei, 대만
- Novartis Investigator Site
-
-
-
-
-
Aalborg, 덴마크
- Novartis Investigator Site
-
Arhus, 덴마크
- Novartis Investigator Site
-
Copenhagen, 덴마크
- Novartis Investigative Site
-
Copenhagen, 덴마크
- Novartis Investigator Site
-
Frederikssund, 덴마크
- Novartis Investigator Site
-
Hellerup, 덴마크
- Novartis Investigator Site
-
Hvidovre, 덴마크
- Novartis Investigator Site
-
Odense, 덴마크
- Novartis Investigator Site
-
Roslev, 덴마크
- Novartis Investigator Site
-
Silkeborg, 덴마크
- Novartis Investigative Site
-
Soborg, 덴마크
- Novartis Investgative Site
-
Vaerloese, 덴마크
- Novartis Investigator Site
-
-
-
-
-
Bad Segeberg, 독일
- Novartis Investigator Site
-
Berlin, 독일
- Novartis Investigator Site
-
Bielefeld, 독일
- Novartis Investigator Site
-
Bochum, 독일
- Novartis Investigator Site
-
Bonn, 독일
- Novartis Investigator Site
-
Bruehl, 독일
- Novartis Investigator Site
-
Cottbus, 독일
- Novartis Investigator Site
-
Dortmund, 독일
- Novartis Investigator Site
-
Dueren, 독일
- Novartis Investigator Site
-
Eggenfelden, 독일
- Novartis Investigator Site
-
Eschwege, 독일
- Novartis Investigator Site
-
Forchheim, 독일
- Novartis Investigator Site
-
Freudenberg, 독일
- Novartis Investigator Site
-
Furth, 독일
- Novartis Investigator Site
-
Gelsenkirchen, 독일
- Novartis Investigator Site
-
Gummersbach, 독일
- Novartis Investigator Site
-
Hagen, 독일
- Novartis Investigator Site
-
Hannover, 독일
- Novartis Investigator Site
-
Kassel, 독일
- Novartis Investigator Site
-
Kempten, 독일
- Novartis Investigator Site
-
Koeln, 독일
- Novartis Investigator Site
-
Landsberg am Lech, 독일
- Novartis Investigator Site
-
Langenfeld, 독일
- Novartis Investigator Site
-
Leipzig, 독일
- Novartis Investigator Site
-
Mainz, 독일
- Novartis Investigator Site
-
Muenchen, 독일
- Novartis Investigator Site
-
Munich, 독일
- Novartis Investigator Site
-
Neuss, 독일
- Novartis Investigator Site
-
Nuremburg, 독일
- Novartis Investigator Site
-
Oschersleben, 독일
- Novartis Investigator Site
-
Ruhmannsfelden, 독일
- Novartis Investigator Site
-
Sinsheim, 독일
- Novartis Investigator Site
-
Solingen, 독일
- Novartis Investigator Site
-
Steinfort-borghorst, 독일
- Novartis Investigator Site
-
Vilshofen, 독일
- Novartis Investigator Site
-
Wallerfing, 독일
- Novartis Investigator Site
-
Witten, 독일
- Novartis Investigator Site
-
-
-
-
-
Ekaterinburg, 러시아 연방
- Novartis Investigator Site
-
Kazan, 러시아 연방
- Novartis Investigator Site
-
Moscow, 러시아 연방
- Novartis Investigator Site
-
Saint Petersburg, 러시아 연방
- Novartis Investigator Site
-
Samara, 러시아 연방
- Novartis Investigator Site
-
St Petersburg, 러시아 연방
- Novartis Investigator Site
-
Yaroslavl, 러시아 연방
- Novartis Investigator Site
-
Yekaterinburg, 러시아 연방
- Novartis Investigator Site
-
-
-
-
-
Bardejov, 슬로바키아
- Novartis Investigator Site
-
Bratislava, 슬로바키아
- Novartis Investigator Site
-
Kosice, 슬로바키아
- Novartis Investigator Site
-
Kovice, 슬로바키아
- Novartis Investigator Site
-
Spisska, 슬로바키아
- Novartis Investigator Site
-
-
-
-
-
Reykhavik, 아이슬란드
- Novartis Investigator Site
-
-
-
-
-
Ancona, 이탈리아
- Novartis Investigator Site
-
Arenzano, 이탈리아
- Novartis Investigator Site
-
Ascoli Piceno, 이탈리아
- Novartis Investigative Site
-
Brescia, 이탈리아
- Novartis Investigator Site
-
Cagliari, 이탈리아
- Novartis Investigator Site
-
Chieti, 이탈리아
- Novartis Investigator Site
-
Ferrara, 이탈리아
- Novartis Investigator Site
-
Milan, 이탈리아
- Novartis Investigator Site
-
Milano, 이탈리아
- Novartis Investigator Site
-
Orbassano, 이탈리아
- Novartis Investigator Site
-
Palermo, 이탈리아
- Novartis Investigator Site
-
Reggio Emilia, 이탈리아
- Novartis Investigator Site
-
Rome, 이탈리아
- Novartis Investigator Site
-
Sesto, 이탈리아
- Novartis Investigator Site
-
Siena, 이탈리아
- Novartis Investigator Site
-
Terni, 이탈리아
- Novartis Investigator Site
-
-
-
-
-
Chennai, 인도
- Novartis Investigator Site
-
Coimbatore, 인도
- Novartis Investigator Site
-
Goa, 인도
- Novartis Investigator Site
-
Hyderabad, 인도
- Novartis Investigator Site
-
Jaipur, 인도
- Novartis Investigator Site
-
Kerala, 인도
- Novartis Investigator Site
-
Mangalore, 인도
- Novartis Investigator Site
-
Mumbai, 인도
- Novartis Investigator Site
-
Vellore, 인도
- Novartis Investigator Site
-
-
-
-
-
Cvikov, 체코 공화국
- Novartis Investigator Site
-
Lovosice, 체코 공화국
- Novartis Investigator Site
-
Novy Jocin, 체코 공화국
- Novartis Investigator Site
-
Pardubice, 체코 공화국
- Novartis Investigator Site
-
Praha, 체코 공화국
- Novartis Investigator Site
-
Zatec, 체코 공화국
- Novartis Investigative Site
-
-
-
-
-
Edmonton, 캐나다
- Novartis Investigative Site
-
Edmonton, 캐나다
- Novartis Investigator Site
-
London, 캐나다
- Novartis Investigator Site
-
Mirabel, 캐나다
- Novartis Investigator Site
-
Montreal, 캐나다
- Novartis Investigator Site
-
Toronto, 캐나다
- Novartis Investigator Site
-
-
-
-
-
Barranquilla, 콜롬비아
- Novartis Investigator Site
-
Bogota D.C., 콜롬비아
- Novartis Investigator Site
-
Medellin, 콜롬비아
- Novartis Investigator Site
-
-
-
-
-
Callao, 페루
- Novartis Investigator Site
-
Miraflores, 페루
- Novartis Investigator Site
-
San Borja, 페루
- Novartis Investigator Site
-
San Isidro, 페루
- Novartis Investigator Site
-
San Martin de Porres, 페루
- Novartis Investigator Site
-
Surco, 페루
- Novartis Investigator Site
-
-
-
-
-
Ambroise, 프랑스
- Novartis Investigative Site
-
Beuvry, 프랑스
- Novartis Investigative Site
-
Ferolles-Attilly, 프랑스
- Novartis Investgative Site
-
Nice, 프랑스
- Novartis Investigator Site
-
-
-
-
-
Hus, 핀란드
- Novartis Investigator Site
-
Jyvaskyla, 핀란드
- Novartis Investigator Site
-
Lahti, 핀란드
- Novartis Investigator Site
-
Oulu, 핀란드
- Novartis Investigator Site
-
Tampere, 핀란드
- Novartis Investigator Site
-
Turku, 핀란드
- Novartis Investigator Site
-
-
-
-
-
Budapest, 헝가리
- Novartis Investigator Site
-
Debrechen, 헝가리
- Novartis Investigator Site
-
Deszk, 헝가리
- Novartis Investigator Site
-
Mosonmagyarovar, 헝가리
- Novartis Investigator Site
-
Szekesfehervar, 헝가리
- Novartis Investigator Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Clinical diagnosis of moderate to severe Chronic Obstructive Pulmonary Disease (COPD) as per the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2006 Guidelines (mandatory) and including:
- Smoking history of at least 20 pack years
- Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) < 80% predicted and >or= 30% of predicted normal value
- Post-bronchodilator FEV1/FVC < 70%
("Post" defined as within 30 minutes of inhalation of 400 µg salbutamol)
Exclusion Criteria:
- Pregnant or nursing (lactating) women and women of child-bearing potential UNLESS they meet pre-specified definitions of post-menopausal or are using pre-specified acceptable methods of contraception
- Hospitalisation for COPD exacerbation in the 6 weeks prior to Visit 1 or during run-in
- Patients requiring oxygen therapy for chronic hypoxemia (typically >15h/day)
- Respiratory tract infection within 6 weeks prior to Visit 1 and during the run-in period
- Concomitant pulmonary disease
- Asthma history (eosinophils > 400/mm3; symptoms prior to age 40). Includes history of childhood asthma
- History of long QTc syndrome or QTc interval > 450 ms for males and >470 ms for females
- Patients who have a clinically significant condition or a clinically relevant laboratory abnormality
- History of reactions to sympathomimetic amines or inhaled medication
- Inability to use the dry powder devices or perform spirometry
- Irregular day/night, wake/sleep cycles, e.g. shift workers
- Certain medications for COPD and allied conditions such as long acting bronchodilators must not be used prior to Visit 1 and for a pre-specified minimum washout period
- Patients unable or unwilling to complete a patient diary
Other protocol-defined inclusion/exclusion criteria may apply.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Indacaterol 150 μg
Indacaterol 150 μg once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study. |
Indacaterol 150 μg once daily (o.d) inhaled
Placebo to salmeterol delivered via a proprietary dry powder inhaler
|
위약 비교기: Placebo
Placebo to Indacaterol once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study. |
Placebo to salmeterol delivered via a proprietary dry powder inhaler
Placebo to Indacaterol inhaled via SDDPI.
|
활성 비교기: Salmeterol 50 μg
Salmeterol 50 μg twice daily delivered via a proprietary dry powder inhaler in the morning and in the evening. Placebo to Indacaterol daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study. |
Placebo to Indacaterol inhaled via SDDPI.
Salmeterol 50 μg twice daily (b.i.d) delivered via a proprietary dry powder inhaler
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment
기간: Week 12
|
Spirometry was conducted according to internationally accepted standards.
Trough FEV1 was defined as the average of the 23 hour 10 minute and 23 hour 45 minute post-dose FEV1 readings.
Mixed model used baseline FEV1, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and 1 hour post inhalation of ipratropium as covariates.
|
Week 12
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
St. George's Respiratory Questionnaire (SGRQ) Total Score After 12 Weeks of Treatment
기간: Week 12
|
SGRQ is a health related quality of life questionnaire consisting of 76 items in three sections: symptoms, activity and impacts.
The total score is 0 to 100 with a higher score indicating poorer health status.
The mixed model used baseline SGRQ total score, FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and one hour post inhalation of ipratropium as covariates.
|
Week 12
|
Percentage of COPD "Days of Poor Control" During 26 Weeks of Treatment
기간: Up to 26 weeks
|
Participants rated their symptoms on a scale of 0=none to 3=severe.
A Chronic Obstructive Pulmonary Disease (COPD) "day of poor control" was defined as any day in the participants diary with a score >=2 (moderate or severe) for at least 2 of 5 symptoms (cough, wheeze, production of sputum, color of sputum, breathlessness).
The mixed model used baseline percentage of "days of poor control", FEV1 prior to and 30 minutes post inhalation of salbutamol/albuterol, and FEV1 prior to and one hour post inhalation of ipratropium as covariates.
|
Up to 26 weeks
|
공동 작업자 및 조사자
스폰서
간행물 및 유용한 링크
일반 간행물
- Jones PW, Mahler DA, Gale R, Owen R, Kramer B. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir Med. 2011 Jun;105(6):892-9. doi: 10.1016/j.rmed.2011.02.013. Epub 2011 Mar 11.
- Worth H, Chung KF, Felser JM, Hu H, Rueegg P. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011 Apr;105(4):571-9. doi: 10.1016/j.rmed.2010.11.027. Epub 2011 Jan 11.
- Yelensky R, Li Y, Lewitzky S, Leroy E, Hurwitz C, Rodman D, Trifilieff A, Paulding CA. A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients. Pharmacogenomics J. 2012 Dec;12(6):484-8. doi: 10.1038/tpj.2011.54. Epub 2011 Dec 13.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CQAB149B2336
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Indacaterol 150 μg에 대한 임상 시험
-
Novartis Pharmaceuticals완전한
-
Centre d'Investigation Clinique et Technologique...완전한
-
Hospital General Universitario Elche알려지지 않은
-
St. Petersburg Research Institute of Vaccines and...완전한
-
Vertex Pharmaceuticals Incorporated완전한
-
Purdue UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)완전한
-
Novartis Pharmaceuticals완전한천식독일, 네덜란드, 영국, 중국, 루마니아, 불가리아